Ipsen, Galderma expand deal for Dysport to key Asia-Pacific territories

6 January 2016

French pharmaceutical company Ipsen (Euronext: IPN) on Wednesday said it has expanded the current distribution agreement for Dysport, with partner Galderma, in aesthetic indications to some Asia-Pacific territories.

The company said the clinical study will be funded by Galderma in exchange for the right to use results of study to support regulatory filing in China.

Marc de Garidel, chief executive of Ipsen said: “We are delighted to further expand our collaboration with Galderma, our key historical partner for the distribution of Dysport the global neurotoxin aesthetic market. Galderma has successfully grown Dysport and Azzalure in aesthetics, while Ipsen’s core strategy has been to reinforce its presence in movement disorders. We are confident that Galderma will also maximize Dysport’s aesthetic potential in the Asia-Pacific Territory.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK